Basit öğe kaydını göster

dc.contributor.authorMutlu, Hasan
dc.contributor.authorGündüz, Şeyda
dc.contributor.authorBüyükçelik, Abdullah
dc.contributor.authorYıldız, Özcan
dc.contributor.authorUysal, Mükremin
dc.contributor.authorTural, Deniz
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorÇoşkun, Hasan Şenol
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:17Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:17Z
dc.date.issued2014en_US
dc.identifier.citationMutlu, H., Gündüz, Ş., Büyükçelik, A., Yıldız, Ö., Uysal, M. Tural, D. ... Çoşkun, H. Ş. (2014). The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. Clinical Genitourinary Cancer, 12(6), 447-450. https://dx.doi.org/10.1016/j.clgc.2014.06.006en_US
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.urihttps://dx.doi.org/10.1016/j.clgc.2014.06.006
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2187
dc.descriptionWOS: 000345547700009en_US
dc.descriptionPubMed ID: 25022784en_US
dc.description.abstractThe effects of cytoreductive nephrectomy (CRN) on prognosis of patients with metastatic renal cell cancer (RCC) using antiangiogenic targeted agents were evaluated. The median overall survival was significantly higher in the group that received CRN (P = .034). We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy. Background: Targeted therapy has improved the survival of patients with metastatic RCC. In the present study, we evaluated whether there was an effect of cytoreductive surgery on prognosis of patients with metastatic RCC using antiangiogenic tyrosine kinase inhibitor (TKI) agents. Patients and Methods: A total of 52 patients with metastatic RCC from Akdeniz University, Afyon Kocatepe University, and Medipol University participated in the study. All the patients had received targeted antiangiogenic therapy after interferon alfa-2b. According to previous CRN, the patients were divided into 2 groups as CRN (+) and CRN (-). Results: The CRN (+) group was younger than the CRN (-) group (P < .001) and the hemoglobin levels were significantly higher in the CRN (+) group (P = .023). The median progression-free survival time from the date of starting TKIs were 8.5 and 3.0 months for the CRN (+) and CRN (-) groups, respectively (P = .104). The median overall survival was 15.1 and 5.4 months for the CRN (+) and CRN (-) groups, respectively (P = .034). Conclusion: We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy. However, the indications of CRN might be limited to good-risk patients with metastatic RCC. Further randomized studies are warranted to clarify the necessity of CRN in patients with metastatic RCC.en_US
dc.language.isoengen_US
dc.publisherCIG Media Groupen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectAngiogenesisen_US
dc.subjectNephrectomyen_US
dc.subjectPrognosisen_US
dc.subjectRenal Cell Canceren_US
dc.subjectSurvivalen_US
dc.titleThe necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2ben_US
dc.typearticleen_US
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume12en_US
dc.identifier.issue6en_US
dc.identifier.startpage447en_US
dc.identifier.endpage450en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.clgc.2014.06.006en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster